Hikma Pharmaceuticals
Pharmaceuticals
HIK.L
GBX 1,973 1.7
$ 5.7 bn
$ 6.7 bn
Carbon footprint
Primary Climate Goal
Hikma Pharmaceuticals aims to reduce Scope 1 + 2 by 25% by 2030 from a base year 2020
This target is most likely outdated and the company appears to have already achieved it
GHG emissions and Carbon intensity
Hikma Pharmaceuticals reported Total CO2e Emissions - Market-Based Scope 1 + Scope 2 for the twelve months ending 31 December 2021 at 117 Kt (-28 /-19.5% y-o-y). Also positively, carbon intensity decreased to 46 t (-16 /-26.2% y-o-y).
Hikma Pharmaceuticals's Scope 3 emissions grew to 830 Kt (
The company is committed to reducing Scope 1 + 2 by 25% by 2030 from a base year 2020, which it appears to have already achieved as of 2021. This target, however, has not been recognised as science-based (and as aligned with Paris Agreement) by the SBTi.
Copyright © 2024 Exerica. All rights reserved.